Carisbamate

Summary

Carisbamate (CHEMBL2087003) is a phase-3 clinical-stage small molecule (ATC N03AX19); indicated across 11 conditions including epilepsy and visual epilepsy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N03AX19
• Indications: 11 conditions
• Clinical trials: 19
• Chemistry: 215.63 Da · C9H10ClNO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2087003
Name	Carisbamate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6918474
ATC	N03AX19
Molecular formula	C9H10ClNO3
Molecular weight	215.63
InChIKey	OLBWFRRUHYQABZ-MRVPVSSYSA-N

SMILES: C1=CC=C(C(=C1)[C@@H](COC(=O)N)O)Cl

IUPAC name: [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate

Also known as: Carisbamate, Carisbamato, JNJ-10234094, RWJ-333369, YKP-509, CARISBAMATE

Patent coverage: 123 distinct patent families (506 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
epilepsy	3	MONDO:0005027	EFO:0000474
visual epilepsy	3	MONDO:0001386	HP:0001250
complex partial epilepsy	3	MONDO:0006710	EFO:1000877
partial motor epilepsy	3	MONDO:0006891	EFO:1001089
movement disorder	2	MONDO:0005395	EFO:0004280
diabetic neuropathy	2	MONDO:0006626	EFO:1000783
migraine disorder	2	MONDO:0005277	MONDO:0005277
alcohol abuse	1	MONDO:0002046	MONDO:0002046
substance-related disorder	1	MONDO:0002494	MONDO:0002491
Lennox-Gastaut syndrome	1	MONDO:0016532	MONDO:0016532

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
PHASE3	9
PHASE2	6
PHASE1	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05219617	PHASE3	RECRUITING	Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT00425282	PHASE3	COMPLETED	A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
NCT00433667	PHASE3	COMPLETED	A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
NCT00563459	PHASE3	TERMINATED	Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.
NCT00697762	PHASE3	TERMINATED	Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
NCT00697918	PHASE3	COMPLETED	Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
NCT00740623	PHASE3	COMPLETED	A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
NCT00744731	PHASE3	COMPLETED	An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
NCT00991757	PHASE3	COMPLETED	An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.
NCT00109083	PHASE2	COMPLETED	A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
NCT00228969	PHASE2	COMPLETED	Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
NCT00492323	PHASE2	COMPLETED	An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).
NCT00501202	PHASE2	COMPLETED	Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).
NCT00524056	PHASE2	COMPLETED	A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
NCT00870454	PHASE2	COMPLETED	An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics
NCT02435381	PHASE1/PHASE2	COMPLETED	Carisbamate as a Potential Treatment for Alcohol Dependence
NCT03731715	PHASE1	COMPLETED	Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
NCT04062981	PHASE1	COMPLETED	Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
NCT04520360	PHASE1	COMPLETED	Bioavailability and Food Effect Study of 3 Types of Carisbamate

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).